HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Abstract
Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.
AuthorsEmily P Thi, Chad E Mire, Raul Ursic-Bedoya, Joan B Geisbert, Amy C H Lee, Krystle N Agans, Marjorie Robbins, Daniel J Deer, Karla A Fenton, Ian MacLachlan, Thomas W Geisbert
JournalScience translational medicine (Sci Transl Med) Vol. 6 Issue 250 Pg. 250ra116 (Aug 20 2014) ISSN: 1946-6242 [Electronic] United States
PMID25143366 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2014, American Association for the Advancement of Science.
Chemical References
  • Antigens, Viral
  • Lipids
  • RNA, Small Interfering
  • RNA, Viral
Topics
  • Animals
  • Antigens, Viral (immunology)
  • Humans
  • Lipids (therapeutic use)
  • Macaca mulatta (immunology, virology)
  • Marburg Virus Disease (pathology, therapy, virology)
  • Marburgvirus (immunology, physiology)
  • Nanoparticles (chemistry, therapeutic use)
  • RNA, Small Interfering (therapeutic use)
  • RNA, Viral (metabolism)
  • Survival Analysis
  • Treatment Outcome
  • Viremia (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: